ORTEXORTEX News
Tracking NTRA? Get live short interest, options flow, and signals on ORTEX.Sign up free →
NT
ConfluenceNTRA

Analysts Pile In, but Options Market Hedges

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 9 Jul 2026, 10:26

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit
ORTEX chart of Natera, Inc. (NTRA) share price and short interest (% of free float), three months to July 7, 2026
ORTEX data as of 9 Jul 2026, 10:26

NTRA has drawn a wave of analyst upgrades over the past two weeks. Now the options market is pushing back.

The put/call ratio hit 0.72 on July 8. That's 2.3 standard deviations above its 20-day mean of 0.66. It's the most elevated options hedging seen on the stock in weeks — and it sits against a backdrop of unusually bullish sell-side conviction.

The Analyst Case

Five firms raised price targets on Natera between June 23 and July 6. Evercore ISI lifted its target to $300. Bernstein reinstated coverage at $310 — the highest target in the group. Guggenheim moved to $290. BTIG raised twice in quick succession, first to $270 then $275. The stock closed July 8 at $274.39.

That means the stock is already trading above three of the five recently revised targets. Bernstein and Evercore remain above the current price. Goldman Sachs sits as the lone dissenter, initiating at Neutral with a $245 target — roughly 11% below where the stock trades today.

The bull case centers on Natera's MRD testing franchise and last week's Japan regulatory approval, which opens an underpenetrated international market. The bear case flags intensifying competition in the MRD landscape and uncertainty around sustaining reimbursement growth.

The Options Pushback

The PCR spike to 0.72 is notable precisely because it happened as the stock pulled back 2.4% on July 8. It's not at an extreme by historical standards — the 52-week high is 1.24 — but the speed of the move relative to the 20-day mean is what stands out.

Put buying at this pace, relative to recent norms, suggests some participants are buying downside protection. That's not unusual after a 27% one-month rally. But the divergence between analyst optimism and options positioning is worth tracking.

Borrow Market: No Signal Here

Short interest sits at 3.1% of free float — low enough that the lending market tells no real story. Availability is at 5,725% of short interest, meaning shares to borrow are abundant. Cost to borrow is 0.56% — firmly in "easy" territory. There is no squeeze pressure from the lending side.

What to Watch

Next earnings: August 6. The stock has moved -10% and -2% on its two most recent prints. With the PCR running elevated and the stock near or above most analyst targets, the options market appears to be pricing in some caution ahead of that date.


  • Price (July 8): $274.39, down 2.4% on the day; +27.4% over one month
  • PCR: 0.72 vs. 20-day mean of 0.66 (z-score: 2.28)
  • Recent target range: $245 (Goldman, Neutral) to $310 (Bernstein, Outperform)
  • SI % FF: 3.1% — low; borrow availability at 5,725%
  • Next earnings: August 6

Against its peers

Shares moved -0.7% over the past week against a median of +1.8% for its closest peers.

Stocks in this article

See the live data behind this article on ORTEX.

Open NTRA on ORTEX →

How this article was generated

Generated
9 Jul 2026, 10:27
Data as of
9 Jul 2026, 10:26
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.